Lymphocyte function alteration following anti-cancer treatment in patients with non-small-cell lung cancer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900027336

Enrollment

Unknown

Registered

2019-11-09

Start date

2019-12-01

Completion date

Unknown

Last updated

2019-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NSCLC

Interventions

Case series:Anti-cancer treatment

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Eligible patients were 18 years or older, with a recent diagnosis of pathologically confirmed NSCLC as the patient's first malignant tumor, an Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less and eligible to receive radiation, chemotherapy or immunotherapy as the only treatment modality, which is generally determined by the stage of the disease.

Exclusion criteria

Exclusion criteria: Patients were excluded if there was incomplete therapy information; or if their source documents were from autopsy or death certificate only.

Design outcomes

Primary

Measure	Time frame
OS;Lymphocyte function;	—

Countries

China

Contacts

Public ContactYuan Xun

Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology

yuanxun@tjh.tjmu.edu.cn+86 15827408306

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026